Article Details

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in ...

Retrieved on: 2021-07-06 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in .... View article details on hiswai:

Excerpt

... with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine and venetoclax.

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up